<DOC>
	<DOCNO>NCT02660138</DOCNO>
	<brief_summary>The purpose study provide confirmatory evidence safety efficacy two Dysport® ( AbobotulinumtoxinA ) dose ( 600 unit [ U ] 800 U ) , compare placebo reduce urinary incontinence ( UI ) adult subject treat neurogenic detrusor overactivity ( NDO ) due spinal cord injury ( SCI ) multiple sclerosis ( MS ) .</brief_summary>
	<brief_title>Dysport® Treatment Urinary Incontinence Adults Subjects With Neurogenic Detrusor Overactivity ( NDO ) Due Spinal Cord Injury Multiple Sclerosis - Study 1</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Key Urinary Incontinence least 3 month prior Screening result Neurogenic Detrusor Overactivity due Spinal Cord Injury Multiple Sclerosis . Subjects Spinal Cord Injury must stable neurological injury T1 level occur least 6 month prior Screening . Subjects Multiple Sclerosis must clinically stable investigator 's opinion , exacerbation ( relapse ) MS least 3 month prior Screening . Subjects must inadequate response least 4 week oral medication use treatment NDO ( e.g . anticholinergic , beta3 agonist ) and/or intolerable sideeffects . Routinely perform Clean Intermittent Catheterization ( CIC ) ensure adequate bladder empty . An average least two episode per day Urinary Incontinence record screen bladder diary . Key Any current condition ( NDO ) may impact bladder function . Previous current , tumour malignancy affect spinal column spinal cord , unstable cause SCI . Any condition prevent cystoscopic treatment administration CIC usage , e.g . urethral stricture . Current indwell bladder catheter , removal indwell bladder catheter le 4 week prior Screening . BTXA treatment within 9 month prior Screening urological condition ( e.g . detrusor urethral sphincter treatment ) . Any neuromodulation/electrostimulation usage urinary symptoms/incontinence within 4 week prior Screening . Any implanted neuromodulation device must switch least 4 week prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>